Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00834210 · ClinicalTrials.gov registry record · Phase 4

Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris

A Phase 4 study, sponsored by Allergan.

Completed
Registry status
Phase 4
Development phase
171
Enrollment target

NCT00834210: Completed Phase 4 study, sponsored by Allergan.

NCT00834210 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 171 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00834210, a Phase 4 study, has completed, sponsored by Allergan.

COMPLETED
Registry status
Phase 4
Development phase
171 participants
Enrollment target

Study Summary

A 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tazarotene cream 0.1% compared with tazarotene cream 0.1% monotherapy in treating moderate to severe facial acne vulgaris

Primary Outcome

Change from baseline in inflammatory lesion count (papules, pustules and nodules) at week 12. Papules and nodules are round, solid elevations of the skin with no visible fluid; papules are smaller (less than 5 or 10 millimeters in width and depth) and nodules are larger (greater than 5 or 10 millimeters in width and depth). Pustules are small elevations of the skin containing cloudy material. A negative number change from baseline indicates a reduction in lesion counts (improvement).

Interventions

  • DRUG Dapsone
  • DRUG Tazarotene

Trial Details

FieldValue
Enrollment Target 171 participants
Start Date 2008-12
Est. Completion 2009-09
Phase Phase 4
Allergan

314 total trials

What the finished NCT00834210 record still lists

NCT00834210 is an interventional study that assigns participants to a tested intervention. The registered 171 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 2 interventions - of which Dapsone is the first listed.

NCT00834210 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00834210 about?

NCT00834210 is a clinical study titled "Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris". A 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tazarotene cream 0.1% compared with tazarotene cream 0.1% monotherapy in treating moderate to severe facial acne vulgaris

What is the current status of trial NCT00834210?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 171 participants. The study started on 2008-12. Estimated completion is 2009-09.

What interventions are being tested in trial NCT00834210?

The interventions under investigation include: Dapsone (DRUG), Tazarotene (DRUG).

Who is sponsoring clinical trial NCT00834210?

This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00834210's enrollment target sits among peer trials

171 484th of 2000 higher than 1,517 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02641145 · 171 participants · NA

    Molecular Imaging of Primary Amyloid Cardiomyopathy

  • NCT05541029 · 171 participants · NA

    Music Listening: A Mechanistic Trial

  • NCT05561127 · 171 participants · Phase 3

    Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel

  • NCT05592938 · 171 participants · NA

    Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00834210, the US trial registry maintained by the National Library of Medicine. NCT00834210 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.